Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3928/23258160-20250619-01 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RWC Update: Combined Phacovitrectomy vs Sequential Surgery; The Dancing Delight; Welding Arc Maculopathy.
Ophthalmic Surg Lasers Imaging Retina
August 2025
Vitreo Retina and Uvea Service, Dr. Shroff’s Charity Eye Hospital, New Delhi, India
CNS Involvement by North American-Adult T-cell Leukemia/Lymphoma Is Associated With Discrete Dissemination Patterns and Molecular Profiles, Involving XPO1 E571 and KLF2/PI3KCD in Selected Cases.
JCO Precis Oncol
July 2025
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
Purpose: CNS involvement in North American adult T-cell leukemia/lymphoma (NA-ATLL) remains poorly understood. This study examined the CNS involvement in patients with ATLL treated at a tertiary hospital in New York City.
Methods: CNS involvement was defined by positive cerebrospinal fluid (CSF) cytology, flow cytometry, positive CNS imaging, or neurological examination findings.
RWC Update: Surgical Intervention in Pediatric Uveitis; L-Shape Technique: Engineering for Intraocular Foreign Bodies; Post-Viral Frosted Branch Angiitis.
Ophthalmic Surg Lasers Imaging Retina
July 2025
RWC Update: Surgical Management of Lamellar Macular Hole; Tamoxifen Retinopathy; Lashed Out: An Eye Injury Story.
Ophthalmic Surg Lasers Imaging Retina
June 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
J Clin Oncol
August 2025
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Purpose: Pirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomized phase III study conducted exclusively in patients with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with cBTKi, and compared pirtobrutinib with investigator's choice (IC) of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR).
Methods: Patients were randomly assigned 1:1 to receive pirtobrutinib (200 mg once daily) or IC of IdelaR or BR, and were stratified by previous use of venetoclax and del(17p).